The development of the MD-Logic algorithm was initiated at the Institute of Endocrinology and Diabetes at the Schneider Children’s Medical Centre of Israel headed by Prof. Moshe Phillip in 2007. The project spawned the creation of DreaMed Diabetes and an agreement with Medtronic, leading to the implementation of the algorithm into the MiniMed 780G system.

The “MD-Logic Artificial Pancreas algorithm,” is an advanced hybrid closed loop system for controlling patient glucose levels. It can alter both basal insulin and provide automatic correction boluses in real time, while changing the way these correction boluses are provided. This process depends on sensor glucose reading dynamics and the information from the insulin pump. The MD-Logic technology’s effectiveness was validated in many clinical studies. The technology was the first to be tested in a multicentre, multinational randomised controlled study in a diabetes camp, as chronicled by a study in the New England Journal of Medicine. In June 2012, the technology was also the first to be used by patients at home, and in 2015 it was the first to receive regulatory approval from EU authorities.

Now, Medtronic is using MD-Logic artificial pancreas algorithm in the automatic correction boluses of its next generation MiniMed 780G system, a system that will be used by many people with type 1 diabetes around the world. Adding this capability to the MiniMed 780G system will fulfil many unmet needs of people with diabetes, such as with controlling glucose around meals. Specifically, it will help mitigate the hyperglycaemia that results from missed or late meal boluses, as well as the hyper- and hypoglycaemia that often result from inaccurate calculation of the carbohydrate content of a meal.

DreaMed Diabetes CEO and co-founder Eran Atlas said: “I would like to congratulate the Diabetes Group at Medtronic and DreaMed founders for achieving this important milestone. We are proud to be a part of the latest update in the Medtronic MiniMed line of products, optimizing the insulin delivery of each user. DreaMed’s partnership with the Medtronic team served as our first step toward fulfilling our dream of bringing and developing different types of solutions dedicated to improving the care and glucose control of people with diabetes. Our current focus is on our DreaMed Advisor platform which is already being adopted by leading diabetes centres in the U.S. We are thrilled that our first professional life mission is live and will have a positive impact on many people around the world.”

Dr. Robert Vigersky, chief medical officer, global medical and clinical affairs for diabetes group at Medtronic, added: “Collaboration is key to driving innovations that make a meaningful difference in the lives of people living with diabetes. Our ongoing work with DreaMed Diabetes over the years has now resulted in a next generation advanced hybrid closed loop that we believe will further simplify diabetes management.”